Skip to main content
. 2021 Oct 26;23(12):79. doi: 10.1007/s11883-021-00972-x

Fig. 2.

Fig. 2

Mean percent changes from baseline in LDL-C levels in HoFH patients treated with evolocumab, alirocumab, or evinacumab, by mutation status. Changes were evaluated at week 12 (TESLA A, TESLA B, TAAUSSIG, ODYSSEY HoFH), week 4 (Gaudet 2017), or week 24 (ELIPSE HoFH)